EXEL is generating the loudest options signal today. The Exelixis put-call ratio hit 1.33. That is 4.1 standard deviations above its 20-day mean of 0.65. Traders are aggressively buying downside protection.
Short interest on EXEL sits at nearly 15% of free float. Bears already have a firm grip. The PCR spike suggests options traders see more pain ahead.
Elsewhere in pharma, VRTX is drawing attention. Vertex announced over $5 billion peak sales potential from its newly acquired Crinetics assets. Options traders will be watching the $134 billion biotech closely for directional bets. LLY also attracted a JP Morgan price target raise to $1,400. Options flows in large-cap pharma are picking up.
NVDA faces a fresh headwind. Reports emerged that DeepSeek is developing its own AI chip. That news hit the $4.7 trillion chip giant mid-session. Put activity in NVDA often spikes on China-related AI competition stories.
Bitcoin miner carries 34% short interest against a thin availability of just 37%. Short squeeze risk is elevated. Call buyers in high-short names like CleanSpark remain active as Bitcoin holdings grew to 13,924 in June.
The broader put hedging demand signals traders are not fully trusting recent rally highs heading into the week.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
